Inclisiran sodium

Inclisiran Sodium (API)

Research Application:
Inclisiran sodium API (Active Pharmaceutical Ingredient) is studied primarily in the field of RNA interference (RNAi) and cardiovascular therapeutics. As a double-stranded siRNA targeting the PCSK9 gene, it is used in preclinical and clinical research to evaluate long-acting gene-silencing strategies for lowering LDL-C (low-density lipoprotein cholesterol). It also serves as a model compound for investigating siRNA delivery systems, stability, and liver-targeted RNA therapeutics.

Function:
Inclisiran sodium API works by silencing the PCSK9 gene in hepatocytes, leading to decreased production of PCSK9 protein. This results in enhanced recycling of LDL receptors and greater clearance of LDL cholesterol from the blood. Its function as a long-acting cholesterol-lowering agent supports its use in treating hypercholesterolemia and reducing the risk of cardiovascular disease. As an API, it forms the core active component in Inclisiran-based drug formulations.